We are live on ! Find out more
DTIL icon

Precision BioSciences

118 hedge funds and large institutions have $231M invested in Precision BioSciences in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 42 increasing their positions, 34 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more capital invested

Capital invested by funds: $156M → $231M (+$74.4M)

24% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 34

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

2% more funds holding

Funds holding: 116118 (+2)

0.14% more ownership

Funds ownership: 1.63%1.76% (+0.14%)

4% less call options, than puts

Call options by funds: $1.39M | Put options by funds: $1.44M

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
118
Holders Change
+2
Holders Change %
+1.72%
% of All Funds
2.09%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
18
Increased
42
Reduced
34
Closed
16
Calls
$1.39M
Puts
$1.44M
Net Calls
-$51K
Net Calls Change
-$198K
Name Holding Trade Value Shares
Change
Change in
Stake
Capital World Investors
1
Capital World Investors
California
$33.9M
BlackRock
2
BlackRock
New York
$33.5M +$2.19M +8,917 +7%
State Street
3
State Street
Massachusetts
$21.6M +$14.8M +60,452 +235%
Vanguard Group
4
Vanguard Group
Pennsylvania
$20.3M +$2.72M +11,100 +16%
ACH
5
ArrowMark Colorado Holdings
Colorado
$20M -$243K -993 -1%
Citadel Advisors
6
Citadel Advisors
Florida
$12.6M +$11.8M +48,200 +2,379%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$9.24M -$924K -3,771 -9%
CA
8
CHI Advisors
New York
$7.11M -$1.33M -5,416 -16%
WHAM
9
Windmill Hill Asset Management
United Kingdom
$6.32M
Geode Capital Management
10
Geode Capital Management
Massachusetts
$5.39M +$387K +1,577 +8%
Millennium Management
11
Millennium Management
New York
$4.78M +$3.57M +14,578 +322%
Northern Trust
12
Northern Trust
Illinois
$4.31M -$104K -424 -2%
Principal Financial Group
13
Principal Financial Group
Iowa
$3.23M +$138K +563 +5%
CAM
14
Cormorant Asset Management
Massachusetts
$2.89M
MSAM
15
Moloney Securities Asset Management
Missouri
$2.85M +$829K +3,383 +42%
WMSA
16
Weiss Multi-Strategy Advisers
New York
$2.73M -$235K -959 -8%
SCM
17
Sio Capital Management
New York
$2.65M -$313K -1,277 -11%
Charles Schwab
18
Charles Schwab
California
$2.44M +$52.9K +216 +2%
ACWM
19
Adams Chetwood Wealth Management
North Carolina
$2.01M -$768K -3,135 -28%
LCM
20
Laurion Capital Management
New York
$1.89M
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.54M +$96.6K +394 +7%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$1.31M +$289K +1,181 +29%
NNP
23
Nachman Norwood & Parrott
South Carolina
$1.29M +$2.7K +11 +0.2%
N
24
Nuveen
North Carolina
$1.28M -$423K -1,727 -25%
Morgan Stanley
25
Morgan Stanley
New York
$1.22M +$225K +920 +23%

DTIL Hedge Fund Activity: Q4 2020 in Review

118 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q4 2020, worth a combined $231M — up 48% from $156M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DTIL positions and 16 closed out — a net gain of 2 holders — while 42 added to existing stakes and 34 trimmed.

The largest buyer was State Street, adding an estimated $14.8M. The largest seller was venBio Partners, exiting entirely with an estimated $8M sold.

  • 118 institutional investors held Precision BioSciences (DTIL) as of Q4 2020, up from 116 in Q3 2020.
  • Funds reported $231M of Precision BioSciences stock for Q4 2020, up 48% quarter-over-quarter.
  • 18 funds opened new Precision BioSciences positions in Q4 2020 and 16 closed out, a net change of +2 holders.
  • The largest Precision BioSciences buyer in Q4 2020 was State Street, an estimated $14.8M added.
  • The largest Precision BioSciences seller in Q4 2020 was venBio Partners, an estimated $8M sold.

Based on aggregated 13F filings for Q4 2020.